Dementia and Alzheimer Disease

Investigators found that certain underrepresented communities were less likely to be eligible for Alzheimer disease trials after the first screening visit.

The position statement considers the diagnosis of dementia, problems in decision making, symptoms and behavioral management, and the relationship between dementia care and society.

The observational study, initiated by Centogene in partnership with Alector, aims to identify and explore the frequency of genetic mutations in patients with frontotemporal dementia.

ATH-1017, an investigational agent designed to focus on network recovery and synaptic signal transition in the brain, will be evaluated in patients on cognition, global, and functional assessments.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 9, 2021.

Janet Woodcock, MD, acting commissioner of the FDA, called for an inquiry by the Office of the Inspector General into possible interactions between agency officials and Biogen that "may have occurred outside of the formal correspondence process."

Since 2016, there has been consistent growth in the number of Alzheimer disease trials sponsored both in part and fully by academic medical centers and/or the National Institutes of Health.

The newly updated label language emphasizes the Alzheimer disease stages in which aducanumab was studied, with no additional changes made to its approval pathway.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

ICER’s health-benefit price benchmark range for aducanumab is $3000 to $8400 per year for patients with early Alzheimer disease, substantially lower than the current $56,000 annual price listing.

Both high PiB and low entorhinal fluorodeoxyglucose as inclusion criteria reduced 3-fold the number of participants needed in a hypothetical trial compared to using only high PiB.

Patients who received high-dose blarcamesine experienced a 14.51-point MDS-UPDRS total score improvement compared to placebo in a phase 2 study of the Anavex Life Sciences agent.

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

Hermona Soreq, PhD, discusses the complexities of aducanumab’s FDA approval, her initial reaction to the news, and whether it might be greenlit by other country’s regulators.

The executive director of the LEAD Coalition calls for greater collaboration and support from government and the healthcare community in order to boost health equity.

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

Eli Lilly plans on submitting a biologics license application for donanemab under the accelerated approval pathway based on data from the phase 2 TRAILBLAZER-ALZ study.

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences provided thoughts on the comfortability of prescribing aducanumab knowing its safety profile.

The decision to grant breakthrough therapy designation was based off the proof-of-concept phase 2b study which explored the impact of lecanemab, formerly BAN2401, on reducing brain amyloid beta and clinical decline.

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed her and her colleague’s initial response to the FDA’s approval of aducanumab.

The CEO of CENTOGENE discussed the recently announced EFRONT study in FTD and the role that rare disease genetic data collection can play in providing insights into disease intervention and treatment.